Chan Anthony T P, Tang Sydney C W
Division of Nephrology, Department of Medicine, Queen Mary Hospital, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Kidney Res Clin Pract. 2022 Nov;41(6):682-698. doi: 10.23876/j.krcp.21.285. Epub 2022 Jul 19.
Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the management of DKD by lowering proteinuria and protecting organs, other novel treatment approaches with good evidence and efficacy that can be used in conjunction with a RAASi or SGLT2i in managing DKD have emerged in the past few years. This review discusses the evidence for glucagon-like peptide-1 receptor agonist, selective mineralocorticoid receptor antagonist, and selective endothelin A receptor antagonist, emerging treatment options for DKD beyond SGLT2 inhibition.
自早期对肾素 - 血管紧张素 - 醛固酮系统抑制剂（RAASi）进行试验以来，糖尿病肾病（DKD）的治疗进展一直较为有限。尽管钠 - 葡萄糖协同转运蛋白2抑制剂（SGLT2i）通过降低蛋白尿和保护器官彻底改变了DKD的管理方式，但在过去几年中，出现了其他有充分证据且有效的新型治疗方法，可与RAASi或SGLT2i联合用于管理DKD。本综述讨论了胰高血糖素样肽 -1受体激动剂、选择性盐皮质激素受体拮抗剂和选择性内皮素A受体拮抗剂的证据，这些是SGLT2抑制之外DKD的新兴治疗选择。
